Department of Medicine 3 – Rheumatology and Immunology

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis (2020) Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, et al. Journal article Acceptance, Usage, and Barriers of Electronic Patient-Reported Outcomes Among German Rheumatologists: Survey Study (2020) Krusche M, Klemm P, Grahammer M, Mucke J, Vossen D, Kleyer A, Sewerin P, Knitza J Journal article Human Fcγ-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in lyme arthritis (2020) Danzer H, Glaesner J, Baerenwaldt A, Reitinger C, Lux A, Heger L, Dudziak D, et al. Journal article Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study (2020) Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airo P, Valentini G, et al. Journal article Neutrophils as main players of immune response towards nondegradable nanoparticles (2020) Bilyy R, Bila G, Vishchur O, Vovk V, Herrmann M Journal article, Review article Type 2 innate lymphoid cells inhibit the differentiation of osteoclasts and protect from ovariectomy-induced bone loss (2020) Omata Y, Frech M, Lucas S, Primbs T, Knipfer L, Wirtz S, Kadono Y, et al. Journal article The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development (2020) Renoux F, Stellato M, Haftmann C, Vogetseder A, Huang R, Subramaniam A, Becker MO, et al. Journal article Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19 (2020) Narasaraju T, Tang BM, Herrmann M, Muller S, Chow VT, Radic M Journal article Agonistic beta 2-adrenergic receptor autoantibodies characterize the aqueous humor of patients with primary and secondary open-angle glaucoma (2020) Hohberger B, Woern M, Lämmer R, Herrmann M, Mardin C, Kruse F, Kunze R, Wallukat G Conference contribution TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL (2020) Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution